Breast cancer subgroup analysis demonstrated PIK3CA mutations with the lowest frequency (10/69; 14.5%) in HR-/ERBB2- tumors and the highest frequency (118/290; 40.7%) in HR+/ERBB2- tumors, while an intermediate frequency of PIK3CA mutations was observed in HR-/ERBB2+ and HR+/ERBB2+ tumors (9/45; 20.0% and 14/54; 25.9%, respectively). This evidence concerns the gene ERBB2 and breast carcinoma.